Exciting Advances for Vivos Therapeutics in Sleep Apnea Treatment

Vivos Therapeutics Recognized for Innovation in Sleep Medicine

LITTLETON, Colo. — Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company specializing in advanced treatments for sleep-related breathing disorders, has made a significant stride in managing obstructive sleep apnea (OSA). The American Medical Association (AMA) has granted new CPT medical codes for all Vivos CARE oral medical devices. These codes are set to take effect, marking a milestone for patients and providers alike.

Impact of New CPT Codes on Patient Care

Kirk Huntsman, Chairman and CEO of Vivos, expressed enthusiasm over this development, emphasizing its relevance to both patients suffering from OSA and the healthcare providers supporting them. With these codes, patients can more easily access vital treatments that are uniquely designed to address their specific needs. The Vivos CARE devices are currently the only product range authorized by the U.S. Food and Drug Administration for treating moderate to severe OSA, ensuring that patients receive cutting-edge care.

Enabling Broader Patient Access

Huntsman noted that this initiative is crucial in enhancing accessibility for a broader demographic, allowing many more individuals to benefit from their proprietary airway remodeling technology. He believes that this innovative process will substantially contribute to improving patient outcomes and drive revenue growth for the company.

Understanding the Recent Changes in the CPT Code Set

The AMA recently announced 420 updates to the Current Procedural Terminology (CPT) for 2025. Among these updates are 270 new codes, 112 deletions, and 38 revisions reflecting the evolution of medical technologies and clinical practices. According to the AMA, these changes aim to contribute to improved healthcare efficiency and outcomes.

AMA’s Vision for Contemporary Clinical Practice

Bruce A. Scott, M.D., President of the AMA, highlighted that the updates to the CPT code set are aimed at ensuring that medical practices align with advancements made in healthcare technology. By improving data-sharing mechanisms, the intent is to enhance patient care while lowering costs, ultimately benefiting everyone involved in the healthcare system.

Vivos Therapeutics Milestones

Mr. Huntsman remarked that the AMA's approval of these CPT codes represents a significant regulatory achievement, building on Vivos’ recent Medicare coverage approvals. This advancement reinforces their dedication to providing treatment options that can transform the lives of patients dealing with OSA, particularly children between the ages of six and seventeen. The codes signify a promising effort to augment accessibility and affordability of vital treatments.

Innovative Solutions Offered by Vivos

Vivos Therapeutics offers a comprehensive approach through the Vivos Method, a clinically validated, non-invasive treatment for OSA. This method combines proprietary CARE appliance therapy with other innovative techniques that alter the anatomical structure of the upper airway, significantly improving airflow and reducing OSA symptoms.

Over the years, Vivos has successfully treated over 45,000 patients globally with the support of more than 2,000 trained dental professionals. Their integrated approach not only addresses OSA but also provides additional support through the VivoScore program for home sleep testing.

Looking Ahead: Vivos Therapeutics' Future

In light of the recent regulatory approvals and the enhanced marketing strategies Vivos is implementing, the future looks bright for this innovative company. Their collaboration with sleep treatment providers is pivotal in promoting the sales of their appliances and ensuring that patients receive premium care options. Vivos Therapeutics is positioned to help even more people across varying demographics engage in effective treatments for their sleep-related conditions.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is dedicated to revolutionizing the treatment of sleep disorders through innovative solutions. With treatments that focus on correcting dentofacial abnormalities, Vivos is committed to improving patient quality of life. For more information about their offerings, visit www.vivos.com.

Frequently Asked Questions

What is the significance of the new CPT codes for Vivos?

The new CPT codes will facilitate better coverage and reimbursement for Vivos treatments, enhancing accessibility for patients suffering from OSA.

How does the Vivos Method work?

The Vivos Method employs non-invasive appliance therapy that alters the jaw's position and soft tissues, improving airflow and significantly alleviating OSA symptoms.

Can children benefit from Vivos treatments?

Yes, Vivos provides treatment options tailored specifically for children ages 6 to 17 who suffer from moderate to severe OSA.

How many patients has Vivos successfully treated?

Vivos has treated over 45,000 patients worldwide, showcasing the effectiveness of their innovative treatment methods.

Where can I find more information about Vivos Therapeutics?

More information about Vivos Therapeutics and their treatments can be found on their official website at www.vivos.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.